Mobile

A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fix...

Update Il y a 4 ans
Reference: EUCTR2005-001128-35

A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fixed combination of dorzolamide and timolol (Cosopt®) in subjects with open-angle glaucoma or ocular hypertension

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate the mean diurnal IOP reducing effect of Xalacom™ administered once daily in the evening is non-inferior to that of Cosopt administered twice daily from Baseline to Week 12.

Inclusion criteria

  • Open-angle glaucoma

Links